Publications

Hogan Lovells Publications

Patent law in Europe: What pharmaceutical companies need to know

With pharmaceutical competition in Europe continuing to evolve, established companies and new market entrants alike need to understand how key patent litigation tools are shaping the...

Hogan Lovells Publications

Administration presents plans to lower drug prices

On May 11, 2018, President Trump and Department of Health and Human Services (HHS) Secretary Alex Azar delivered highly anticipated speeches regarding the administration's plan to reduce...

Hogan Lovells Publications

China Drug Administration publishes a key Draft Guidance on data exclusivity for pharmaceuticals

This is the first time the China Drug Administration (CDA) provides details on how the data exclusivity applies to pre-clinical and clinical data submitted to the agency. Companies with...

Hogan Lovells Publications

Outlook for OTC drug regulation

Significant change is on the horizon for the over-the-counter (OTC) drug industry. OTC drug sales have grown from about US$3 billion in 1972 to over US$34 billion today, with over 300,000...

Hogan Lovells Publications

UK M&A: Brexit and investment in UK life sciences

While Brexit is likely to result in sweeping changes to the UK’s life sciences sector, the rate of M&A and foreign investment is a positive sign that the region will uphold its...

Published Works

China: Breaking Down the “Great Wall”?

Driven by rapid economic growth and the world’s largest rapidly aging population, China’s pharmaceutical market has become the second largest worldwide, only...

Hogan Lovells Publications

Expanding access to unapproved treatments through right-to-try

State-level right-to-try laws have given patients and their families hope that they might gain access to breakthrough investigational treatments. But traditionally, the FDA and...

Hogan Lovells Publications

A road map to successful life sciences transactions in Europe

U.S. based life sciences companies considering transactions in Europe may easily become overwhelmed with the complexity of Europe’s various jurisdictions.

;
Loading data